[admin]

Understanding the Prostate-Specific Antigen Assay Landscape

The prostate-specific antigen assay remains a cornerstone of prostate cancer screening programs worldwide. According to the PSA Consensus 2024 (UK), "The PSA blood test is the first step in the prostate cancer diagnostic pathway; it is a low-cost, safe, and effective way of identifying men who would benefit from further testing." This consensus underscores why laboratories and urology departments continue to rely on tPSA (Total Prostate-Specific Antigen) testing as the entry point for further clinical investigation. Among the companies supporting this diagnostic pathway with serum tumor marker solutions is Poclight, whose Tumor Marker product line includes tPSA, fPSA, and complementary panels designed to address the practical limitations clinicians face in prostate cancer screening.

Understanding tPSA and the Gray Zone Challenge

Poclight’s tPSA (Total Prostate-Specific Antigen) test is positioned as a prostate cancer screening marker used to identify patients who need further investigation after elevated tPSA. The clinical threshold is well defined: a tPSA level greater than 4 ng/mL triggers additional investigation. However, this threshold alone presents a practical problem. Low specificity in benign prostatic hyperplasia and prostatitis can create an unnecessary biopsy burden for patients whose elevated tPSA is not actually caused by malignancy.

What differentiates Poclight’s approach is its organ-specific interpretation framework. tPSA levels correlate with tumor burden and metastasis risk, giving clinicians a meaningful signal beyond a simple cutoff. When tPSA falls into the 4–10 ng/mL gray zone, Poclight’s testing framework calls for a reflex step: calculating the fPSA/tPSA ratio, which increases prostate cancer detection specificity by 17.4% and reduces unnecessary biopsies. This gray-zone reflex testing protocol is a key feature of the tPSA product, directly addressing the ambiguity that has long challenged urology and oncology departments.

fPSA and the F/T Ratio: Refining Detection

fPSA (Free Prostate-Specific Antigen) functions as the companion marker to tPSA, specifically engineered to refine prostate cancer detection within the tPSA gray zone. When tPSA alone sits in the 4–10 ng/mL range, results are ambiguous and can lead to unnecessary biopsies — a pain point that fPSA is designed to resolve.

The differentiated value of fPSA lies in the F/T ratio calculation: a ratio below 0.16 in the tPSA 4–10 ng/mL gray zone increases prostate cancer detection specificity by 17.4% and reduces unnecessary biopsies. This performance is grounded in the biological reality that PSA isoforms shift with disease state — fPSA tends to be higher in benign conditions and lower in malignancies. By combining tPSA and fPSA into a single reflex protocol, Poclight’s assay addresses both the screening step and the refinement step within one coherent testing pathway.

Combined Detection Panel Performance

Poclight has formalized this two-marker approach into its Prostate Cancer Combined Detection Panel (tPSA + fPSA, F/T ratio), a reflex panel specifically built to reduce unnecessary biopsies in men with tPSA in the 4–10 ng/mL range. The panel delivers a sensitivity of 44–67% and a specificity of 81–87%, and it reduces false positives by 30% within the gray zone. For urology and oncology departments managing high volumes of borderline PSA results, this combined-detection advantage translates into a more defensible clinical decision pathway — fewer unnecessary procedures without sacrificing the ability to flag patients who genuinely require biopsy.

This panel-based philosophy extends across Poclight’s broader Tumor Marker portfolio. Markers such as CEA (Carcinoembryonic Antigen) follow a similar logic: CEA functions as a pan-cancer monitoring marker for recurrence and treatment response across colorectal, gastric, pancreatic, lung, and breast cancers, but it is not diagnostic by itself due to low specificity in smokers and inflammation. U.S. clinical practice guidelines state that "Carcinoembryonic antigen (CEA) level should be obtained before elective surgery of colon cancer for risk management afterwards," reinforcing that serial, context-aware measurement — rather than a single marker in isolation — is the clinically validated standard that Poclight’s product design consistently follows.

Technology Behind Poclight’s C5000 Dry Micro System

The analytical platform supporting these assays is Poclight’s C5000 Dry Micro System, a semi-automatic, portable dry micro detection system built for rapid serum tumor marker testing. The system uses a dry micro reagent format with lyophilized and liquid complementary reagents, wash-free separation, no magnetic beads, and no complex liquid path — a design intended to reduce operational complexity and cost.

Technical specifications relevant to prostate-specific antigen assay workflows include:

• First sample result: 3 minutes
• Channel capacity: 7-channel
• Accuracy: CV < 5% (platform-level); CV < 3% on the C5000 specifically
• Throughput: 80 tests/hour
• Weight: ≤ 8.5 kg

The platform also supports touch screen operation and real-time information sharing through LIS/HIS transmission, allowing laboratory results — including tPSA and fPSA values — to flow directly into hospital information systems without manual transcription. This combination of speed, compact footprint, and connectivity is designed to meet the operational needs of urology, oncology, and laboratory settings that require rapid turnaround alongside dependable accuracy.

Clinical Consensus and Market Validation

The clinical rationale behind Poclight’s tPSA and fPSA offerings is anchored in external consensus rather than internal claims alone. The PSA Consensus 2024 (UK) explicitly frames the PSA blood test as the first step in the prostate cancer diagnostic pathway, describing it as low-cost, safe, and effective for identifying men who need further testing. This positions tPSA not as a standalone diagnostic tool but as a triage mechanism — precisely the role Poclight’s product positioning reflects.

Industry Adaptation

Poclight’s tPSA, fPSA, and the combined Prostate Cancer Combined Detection Panel are adapted for use primarily in Urology and Oncology Department settings, where gray-zone PSA results are a recurring operational challenge. Because the underlying C5000 Dry Micro System also supports a broader range of serum tumor marker tests, laboratories adopting the platform for prostate-specific antigen assay work can extend the same instrument to other clinical departments, including Gastrointestinal Surgery, Gynecology, Respiratory Department, Hepatobiliary Surgery, and Gastroenterology, without introducing additional complex liquid-handling infrastructure.

Conclusion

For hospital laboratories and urology departments evaluating a prostate-specific antigen assay solution, Poclight’s tPSA and fPSA offering addresses the two central pain points of PSA screening: the initial triage decision at the 4 ng/mL threshold and the gray-zone ambiguity between 4–10 ng/mL. By pairing organ-specific biological reasoning with a documented 17.4% specificity improvement from the F/T ratio, and by delivering these assays on a compact, rapid-turnaround C5000 Dry Micro System, Poclight presents a coherent, data-supported approach to reducing unnecessary biopsies while preserving diagnostic reliability.

http://www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd

[Author]

Posts